Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Temsirolimus. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A known ✓ | P62942 | 8/20 | 0.84 |
| ▸ | MTOR | P42345 | 8/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 2/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.85 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.85 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.85 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 3/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temsirolimus SCHEMBL14655780 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL12731651 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL16848395 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL799689 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL13610010 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL6851809 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL18931150 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL16848394 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL19666839 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 | |
| Temsirolimus SCHEMBL21960607 | 1.00 | MTOR (1.00) | MTORABCC3ABCC4ABCB11ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 27007 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144866-A1 | METHODS, DEVICES, AND SYSTEMS FOR PREDICTING TREATMENT RESPONSIVENESS OF CLEAR CELL RENAL CELL CARCINOMA PATIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | OLEMA PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107416-A1 | SINGLE DOSAGE FORMS CONTAINING ELRAGLUSIB AND AT LEAST ONE OTHER ACTIVE INGREDIENT | ACTUATE THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-2303288-A2 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES | Ramot at Tel-Aviv University Ltd. (IL) | 2011-04-06 | — | — | EP | claimed |
| EP-2259844-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | Vicus Therapeutics SPE 1, LLC (US) | 2010-12-15 | — | — | EP | claimed |
| US-20100310503-A1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2010-12-09 | — | — | US | claimed |
| EP-2200431-A1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | Boston Biomedical, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| US-20100040537-A1 | antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases | ABBOTT LABORATORIES (US) | 2010-02-18 | — | — | US | claimed |
| WO-2010017331-A1 | SIGNAL PATHWAY ALTERATIONS AND DRUG TARGET ELEVATIONS IN PRIMARY METACHRONOUS METASTATIC COLORECTAL CANCER COMPARED TO NON-METASTATIC DISEASE | GEORGE MASON INTELLECTUAL PROPERTIES, INC. (US) | 2010-02-11 | — | — | WO | claimed |
| WO-2010006059-A1 | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-01-14 | — | — | WO | claimed |
| WO-2009141823-A2 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2009-11-26 | — | — | WO | claimed |
| WO-2009111648-A1 | COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES | VICUS THERAPEUTICS, LLC (US) | 2009-09-11 | — | — | WO | claimed |
| WO-2009036101-A1 | NOVEL COMPOSITIONS AND METHODS FOR CANCER TREATMENT | BOSTON BIOMEDICAL, INC. (US) | 2009-03-19 | — | — | WO | claimed |